article thumbnail

€30m raised for first-in-class in vivo cell reprogramming platform

Drug Discovery World

The therapy has achieved preclinical proof of concept (PoC) in patient-derived ex vivo models as well as rodent in vivo models, inducing strong anti-tumour immunity and abscopal effect, even in a monotherapy setting. This financing also follows a strong pre-clinical package providing PoC for AT-108.

In-Vivo 52
article thumbnail

Merck and Orna partner for RNA technology-based vaccines and therapies

Pharmaceutical Technology

oRNA molecules have been demonstrated to possess increased stability in vivo compared to linear mRNA and can potentially create more quantities of therapeutic proteins within the body. . These molecules synthesised newly are packaged densely into custom lipid nanoparticles (LNPs), which Orna has made to act on the body’s crucial tissues.

RNA 147
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Start-up aims to advance transformative genetic medicines

Drug Discovery World

Aera’s goal is to change this.” The company’s protein nanoparticle (PNP) genetic medicine delivery platform is based on the discovery of endogenous, human proteins derived from retroelements that can self-assemble to form capsid-like structures and which can package and transfer nucleic acid cargo.

article thumbnail

Medicines Discovery Catapult relaunches Wolfson Radiochemistry facility in Manchester

pharmaphorum

The combination of MDC’s in vivo imaging and infrastructure, with WMIC’s heritage in radiochemistry, further strengthens the national PET Network, which has been established across the UK by MDC and leading academic centres of excellence. ” Find out more about MDCs PET Imaging expertise here.

article thumbnail

A PSA on PSGs: PSG Meetings Are Now Available

FDA Law Blog

A PSG teleconference is a forum for applicants to obtain feedback on the impact of a new or revised PSG on an in-progress development program for which in vivo bioequivalence studies have either commenced or completed. Meeting package content, timing of submission, and directions for submission are also covered by this Guidance.

article thumbnail

THE RISING REALM: BIOPRESERVATION MEDIA INDUSTRY

Roots Analysis

Biopreservation is the exclusive biological approach designated for the preservation of cells, tissues and organs ex-vivo for the purpose of storage, shipment and transportation. Biopreservation media is one of the most crucial entity in conferring effectiveness. F) to 8°C (46.4°F).

article thumbnail

Intellia, Regeneron ace first trial with ‘in vivo’ CRISPR drug

pharmaphorum

So far, human trial data for gene-editing drugs have been generated for ex vivo therapies, meaning the CRISPR technology is used to modify cells outside the body, which are then reinfused into the patient. — Eric Topol (@EricTopol) June 26, 2021. — Eric Topol (@EricTopol) June 26, 2021.

In-Vivo 104